Metastatic Breast Cancer - Pipeline Review, H1 2014


#196411

589pages

Global Markets Direct

$ 2000

In Stock

This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects.

 

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Metastatic Breast Cancer
  • and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Metastatic Breast Cancer
  • pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

 

Reasons to buy

 

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Content

 

 

Table of Contents 2
Introduction 7
Metastatic Breast Cancer Overview 8
Therapeutics Development 9
Metastatic Breast Cancer - Therapeutics under Development by Companies 11
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 18
Metastatic Breast Cancer - Pipeline Products Glance 20
Metastatic Breast Cancer - Products under Development by Companies 24
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 32
Metastatic Breast Cancer - Companies Involved in Therapeutics Development 33
Metastatic Breast Cancer - Therapeutics Assessment 116
Drug Profiles 135
Metastatic Breast Cancer - Recent Pipeline Updates 420
Metastatic Breast Cancer - Dormant Projects 555
Metastatic Breast Cancer - Discontinued Products 561
Metastatic Breast Cancer - Product Development Milestones 563
 

Appendix 572

 

Number of Products under Development for Metastatic Breast Cancer, H1 2014 25

Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2014 26

Number of Products under Development by Companies, H1 2014 28

Number of Products under Development by Companies, H1 2014 (Contd..1) 29

Number of Products under Development by Companies, H1 2014 (Contd..2) 30

Number of Products under Development by Companies, H1 2014 (Contd..3) 31

Number of Products under Development by Companies, H1 2014 (Contd..4) 32

Number of Products under Development by Companies, H1 2014 (Contd..5) 33

Number of Products under Investigation by Universities/Institutes, H1 2014 35

Comparative Analysis by Late Stage Development, H1 2014 36

Comparative Analysis by Clinical Stage Development, H1 2014 37

Comparative Analysis by Early Stage Development, H1 2014 38

Comparative Analysis by Unknown Stage Development, H1 2014 39

Products under Development by Companies, H1 2014 40

Products under Development by Companies, H1 2014 (Contd..1) 41

Products under Development by Companies, H1 2014 (Contd..2) 42

Products under Development by Companies, H1 2014 (Contd..3) 43

Products under Development by Companies, H1 2014 (Contd..4) 44

Products under Development by Companies, H1 2014 (Contd..5) 45

Products under Development by Companies, H1 2014 (Contd..6) 46

Products under Development by Companies, H1 2014 (Contd..7) 47

Products under Investigation by Universities/Institutes, H1 2014 48

Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 49

Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2014 50

Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 51

Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 52

Metastatic Breast Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 53

Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2014 54

Metastatic Breast Cancer - Pipeline by Adherex Technologies Inc., H1 2014 55

Metastatic Breast Cancer - Pipeline by AstraZeneca PLC, H1 2014 56

Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2014 57

Metastatic Breast Cancer - Pipeline by Viralytics Ltd., H1 2014 58

Metastatic Breast Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 59

Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2014 60

Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2014 61

Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2014 62

Metastatic Breast Cancer - Pipeline by Bavarian Nordic A/S, H1 2014 63

Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2014 64

Metastatic Breast Cancer - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 65

Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2014 66

Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2014 67

Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 68

Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 69

Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2014 70

Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 71

Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2014 72

Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2014 73

Metastatic Breast Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 74

Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2014 75

Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2014 76

Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2014 77

Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 78

Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2014 79

Metastatic Breast Cancer - Pipeline by Cell Therapeutics, Inc., H1 2014 80

Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2014 81

Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2014 82

Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2014 83

Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2014 84

Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014 85

Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2014 86

Metastatic Breast Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 87

Metastatic Breast Cancer - Pipeline by Array BioPharma Inc., H1 2014 88

Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2014 89

Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 90

Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 91

Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2014 92

Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2014 93

Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2014 94

Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2014 95

Metastatic Breast Cancer - Pipeline by Insys Therapeutics, Inc., H1 2014 96

Metastatic Breast Cancer - Pipeline by Supratek Pharma Inc., H1 2014 97

Metastatic Breast Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2014 98

Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2014 99

Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2014 100

Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2014 101

Metastatic Breast Cancer - Pipeline by Immutep S.A., H1 2014 102

Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2014 103

Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 104

Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2014 105

Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2014 106

Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2014 107

Metastatic Breast Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 108

Metastatic Breast Cancer - Pipeline by Regulus Therapeutics Inc., H1 2014 109

Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2014 110

Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2014 111

Metastatic Breast Cancer - Pipeline by Zyngenia, Inc., H1 2014 112

Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2014 113

Metastatic Breast Cancer - Pipeline by Polaris Group, H1 2014 114

Metastatic Breast Cancer - Pipeline by Neopharm Ltd., H1 2014 115

Metastatic Breast Cancer - Pipeline by EirGen Pharma Ltd., H1 2014 116

Metastatic Breast Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2014 117

Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2014 118

Metastatic Breast Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 119

Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2014 120

Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2014 121

Metastatic Breast Cancer - Pipeline by Theracrine, Inc., H1 2014 122

Metastatic Breast Cancer - Pipeline by Agonox, H1 2014 123

Metastatic Breast Cancer - Pipeline by Curaxys, S.L., H1 2014 124

Metastatic Breast Cancer - Pipeline by NobelProcera Innovation Centre, Quebec, H1 2014 125

Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2014 126

Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2014 127

Metastatic Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 128

Metastatic Breast Cancer - Pipeline by Galileo Research s.r.l., H1 2014 129

Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2014 130

Metastatic Breast Cancer - Pipeline by Pharmapraxis, H1 2014 131

Assessment by Monotherapy Products, H1 2014 132

Assessment by Combination Products, H1 2014 133

Number of Products by Stage and Target, H1 2014 136

Number of Products by Stage and Mechanism of Action, H1 2014 142

Number of Products by Stage and Route of Administration, H1 2014 147

Number of Products by Stage and Molecule Type, H1 2014 150

Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2014 436

Metastatic Breast Cancer - Dormant Projects, H1 2014 571

Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2014 572

Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2014 573

Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2014 574

Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2014 575

Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2014 576

Metastatic Breast Cancer - Discontinued Products, H1 2014 577

Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2014 578

 

Number of Products under Development for Metastatic Breast Cancer, H1 2014 25

Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2014 26

Number of Products under Development by Companies, H1 2014 27

Number of Products under Investigation by Universities/Institutes, H1 2014 34

Comparative Analysis by Late Stage Products, H1 2014 36

Comparative Analysis by Clinical Stage Development, H1 2014 37

Comparative Analysis by Early Stage Products, H1 2014 38

Assessment by Monotherapy Products, H1 2014 132

Assessment by Combination Products, H1 2014 133

Number of Products by Top 10 Target, H1 2014 134

Number of Products by Stage and Top 10 Target, H1 2014 135

Number of Products by Top 10 Mechanism of Action, H1 2014 140

Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 141

Number of Products by Top 10 Route of Administration, H1 2014 146

Number of Products by Stage and Top 10 Route of Administration, H1 2014 147

Number of Products by Top 10 Molecule Type, H1 2014 148

Number of Products by Stage and Top 10 Molecule Type, H1 2014 149